PMID- 36139674
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 18
DP  - 2022 Sep 17
TI  - Platinum Plus Tegafur-Uracil versus Platinum Alone during Concurrent 
      Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A 
      Propensity-Score-Matching Analysis.
LID - 10.3390/cancers14184511 [doi]
LID - 4511
AB  - Concurrent chemoradiotherapy (CCRT) with a cisplatin-based regimen is the 
      standard treatment for patients with nasopharyngeal carcinoma (NPC). Our study 
      was a propensity-score-matching analysis and it aimed to investigate the 
      oncologic outcomes of platinum plus tegafur-uracil versus platinum alone during 
      CCRT in patient with nonmetastatic NPC. Patients with pathologic confirmed NPC in 
      2018-2022 were reviewed. Patients treated with platinum plus tegafur-uracil 
      (CCRT-UP) or platinum alone (CCRT-P) during CCRT were recruited into this study. 
      A propensity-score-matching analysis was conducted to diminish the selection 
      bias. The recurrence-free survival (RFS) and overall survival (OS) were presented 
      with Kaplan-Meier curves. The treatment-related adverse effects (AEs) were 
      recorded according to the National Cancer Institute's Common Terminology Criteria 
      V3.0. A total of 44 patients with CCRT-UP and 44 patients with CCRT-P were 
      identified after propensity score matching. The median RFS was not reached (NR) 
      in the CCRT-UP group, and it was 12.5 months in the CCRT-P group (p < 0.001). The 
      median OS was NR in the CCRT-UP group, and it was 15.9 months in the CCRT-P group 
      (p < 0.001). The overall response rate and disease-control rate were 
      insignificant between the CCRT-UP and CCRT-P groups. A subgroup analysis showed 
      that the median OS was significantly longer in the CCRT-UP group than in the 
      CCRT-P group, regardless of the clinical stage. A multivariate analysis exhibited 
      that CCRT-UP was independently correlated with survival. The grade 3-4 AEs were 
      insignificant between the CCRT-UP and CCRT-P arms. CCRT-UP had better RFS and OS 
      in nonmetastatic NPC patients with similar toxic profiles. Further larger-scaled 
      prospective randomized control trials are warranted to validate our conclusions.
FAU - Lien, Ching-Feng
AU  - Lien CF
AD  - Department of Otolaryngology, E-Da Hospital, Kaohsiung 824005, Taiwan.
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
FAU - Wang, Chien-Chung
AU  - Wang CC
AD  - Department of Otolaryngology, E-Da Hospital, Kaohsiung 824005, Taiwan.
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
FAU - Yang, Chuan-Chien
AU  - Yang CC
AD  - Department of Otolaryngology, E-Da Hospital, Kaohsiung 824005, Taiwan.
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
FAU - Wang, Chih-Chun
AU  - Wang CC
AD  - Department of Otolaryngology, E-Da Hospital, Kaohsiung 824005, Taiwan.
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
FAU - Hwang, Tzer-Zen
AU  - Hwang TZ
AD  - Department of Otolaryngology, E-Da Hospital, Kaohsiung 824005, Taiwan.
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
FAU - Shih, Yu-Chen
AU  - Shih YC
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
AD  - Department of Otolaryngology, E-Da Cancer Hospital, Kaohsiung 82445, Taiwan.
FAU - Yeh, Shyh-An
AU  - Yeh SA
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
AD  - Department of Radiation Oncology, E-Da Hospital, Kaohsiung 82445, Taiwan.
FAU - Hsieh, Meng-Che
AU  - Hsieh MC
AD  - College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
AD  - Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung 82445, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20220917
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9496885
OTO - NOTNLM
OT  - chemoradiotherapy
OT  - nasopharyngeal carcinoma
OT  - prognosis
OT  - survival
OT  - tegafur-uracil
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/17
CRDT- 2022/09/23 01:07
PHST- 2022/08/29 00:00 [received]
PHST- 2022/09/13 00:00 [revised]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/09/23 01:07 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/17 00:00 [pmc-release]
AID - cancers14184511 [pii]
AID - cancers-14-04511 [pii]
AID - 10.3390/cancers14184511 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Sep 17;14(18):4511. doi: 10.3390/cancers14184511.